| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-invasive alternative to surgical diagnosis for endometriosis
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.
The study, "Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Females Presenting with Symptoms of Endometriosis," is designed to evaluate the clinical performance of MET™ compared to laparoscopic diagnosis, which is currently considered the gold standard for confirming endometriosis. The prospective study will enroll up to 1,000 participants who are referred for diagnostic laparoscopy. Each participant will complete a symptom questionnaire and provide a pre-operative blood sample.
The first participating clinical site, Dedicated to Women OB/GYN, located in Dover, DE, is now beginning enrollment. "This very exciting research could allow women to obtain an accurate diagnosis of endometriosis approximately 2-3 years sooner on average and begin more targeted therapy for their disease process than is currently available. We at Dedicated to Women are honored to team with Pearsanta to bring this groundbreaking technology to the women of Delaware," said Dr. Robert Hartmann, Principal Investigator of the site.
Posted In: ADTX
